A genetically encoded multifunctional trail trimer facilitates cell-specific targeting and tumor cell killing

Molecular Cancer Therapeutics

Volumn 9, Issue 7, 2010, Pages 2142-2151

  Spitzer, Dirk ^a   McDunn, Jonathan E ^a   Plambeck Suess, Stacey ^a   Goedegebuure, Peter S ^a   Hotchkiss, Richard S ^a   Hawkins, William G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL KILLING; CELL SPECIFICITY; CELL VIABILITY; DNA MODIFICATION; ERYTHROCYTE MEMBRANE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN TARGETING; TUMOR CELL; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL LINE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ERYTHROCYTE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; JURKAT CELL LINE; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; PANCREATIC NEOPLASMS; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954569147     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0225     Document Type: Article

References (31)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
2. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999;96:245-54.
3. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30. (Pubitemid 37328939)
4. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85.
5. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178-94.
6. de Vries EG, Gietema JA, de Jong S. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res 2006;12:2390-3.
7. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
9. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75. (Pubitemid 36511833)
10. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009;66:841-51.
11. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39:1462-75.
12. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
13. Garber K. New apoptosis drugs face critical test. Nat Biotechnol 2005;23:409-11.
14. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 2007;11:1299-314.
15. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 2007;179:2600-8.
16. Spitzer D, Unsinger J, Bessler M, Atkinson JP. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 2004;40:911-9.
17. Dirks W, Schaper F, Kirchhoff S, Morelle C, Hauser H. A multifunctional vector family for gene expression in mammalian cells. Gene 1994;149:387-8.
18. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31:229-34.
19. Krippner-Heidenreich A, Grunwald I, Zimmermann G, et al. Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 2008;180:8176-83.
20. Ten CB, Bremer E, de Bruyn M, et al. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009;23:1389-97.
21. Bremer E, de Bruyn M, Samplonius DF, et al. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. J Mol Med 2008;86:909-24.
22. Bremer E, Kuijlen J, Samplonius D, Walczak H, de LL, Helfrich W. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004;109:281-90.
23. Bodmer JL, Meier P, Tschopp J, Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000;275:20632-7.
24. Griffith TS, Stokes B, Kucaba TA, et al. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009;9:9-19.
25. Spitzer D, Unsinger J, Mao D, Wu X, Molina H, Atkinson JP. In vivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane. J Immunol 2005;175:7763-70.
26. Mongkolsapaya J, Grimes JM, Chen N, et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999;6:1048-53.
27. Hymowitz SG, Christinger HW, Fuh G, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999;4:563-71.
28. Cha SS, Kim MS, Choi YH, et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999;11:253-61.
29. Cha SS, Sung BJ, Kim YA, et al. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem 2000;275:31171-7.
30. Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005;280:2205-12.
31. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Nongenetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009;459:428-32.